Fribourg study finds LSD may improve motor learning

A single 100 microgram dose of LSD was linked to 32.8% greater motor learning consolidation than a placebo. That result comes from a controlled study led by researchers at the University of Fribourg and published on September 25, 2026. The experiment examined what happened after participants learned a short sequence of piano keys, giving researchers a precise task through which to measure the retention and improvement of a newly acquired movement.

The result appeared after the initial learning session, rather than while participants were first practising. Eighty minutes after training, the progress made by people who had taken LSD the previous day exceeded the progress recorded in the placebo condition by 32.8%.

The finding places a familiar psychedelic substance inside a tightly defined neuroscience experiment. It does not establish that LSD improves everyday coordination, musical ability, or athletic performance. The study measured one form of motor learning in a small group of healthy participants. Researchers say the result requires further investigation before anyone can draw conclusions about treatment or rehabilitation.

For Switzerland, the work adds to research from a university with a strong presence in psychiatry and neuroscience. It also revives a question with direct clinical relevance: whether altered states can influence how the brain stores newly learned movements.

The study involved 43 people who learned the same piano sequence under LSD and placebo conditions. Each participant was asked to perform the sequence after receiving a single 100 microgram dose of LSD and again after receiving a placebo. The design allowed the researchers to compare the effect of the substance against a control condition within the experiment.

The researchers did not report a measurable advantage during the learning phase itself. The difference emerged during consolidation, the period in which the brain stabilises and strengthens a newly learned skill. In the experiment, the later progress of the LSD condition was 32.8% higher than that of the placebo condition, with testing conducted 80 minutes after the training session.

That distinction matters. The result points towards a possible effect on how learning is retained or refined after practice, rather than evidence that LSD immediately makes a person better at performing a task. The piano exercise also offered a controlled measurement, unlike broad self assessments of creativity, focus, or productivity.

The source report does not provide a larger clinical outcome, a performance benefit outside the task, or evidence that the participants could apply the skill more effectively in daily life. Those unanswered questions limit the result while giving future studies a clear direction.

The researchers have not identified why LSD produced the reported advantage. Abigail Calder, the study's lead researcher at the University of Fribourg's Laboratory of Molecular Psychiatry, said the work was, to the team's knowledge, the first controlled study to show improved motor learning after a psychedelic substance.

Several explanations remain possible. Calder and colleagues point to greater brain plasticity after LSD, along with changes in attention or motivation. Brain plasticity describes the capacity of neural systems to change with experience. If the substance alters that process, it could affect the period after practice when new movements become more stable. Changes in attention or motivation could also influence how participants approached the task and how consistently they performed it.

The current experiment cannot separate those mechanisms. Participants knew when they had taken LSD, which can shape expectations and behaviour. That limitation becomes especially important when researchers assess subjective effects. One week after the experiment, participants reported lower stress and, in some cases, greater mental flexibility. The authors cautioned that expectations may have influenced those reports.

The motor result came from a more concrete performance task, but it still requires replication with larger samples, stronger masking, and additional measures of brain activity and behaviour.

The study does not recommend LSD for patients, and it did not test people recovering from illness or injury. Calder explicitly said the findings do not constitute a recommendation for clinical use. The participants were healthy, so the experiment cannot show whether LSD would help people relearn movement after a stroke, traumatic brain injury, or another neurological condition.

The possible connection to rehabilitation is nevertheless clear. Patients often need to repeat carefully structured movements to regain control of an arm, hand, or leg. A substance that changed the consolidation of motor skills could eventually become relevant to rehabilitation research, provided future trials establish safety, benefit, dose, timing, and the role of supervised therapy.

That path would involve substantial safeguards. Researchers would need to determine whether the effect survives in older adults and patients with neurological conditions. They would also need to examine adverse reactions, interactions with medication, the influence of expectation, and whether any improvement lasts beyond the short testing window used in the Fribourg experiment.

For now, the evidence supports a research hypothesis rather than a medical intervention. Switzerland's clinicians and patients should read the 32.8% figure as an early signal from a small controlled study, not as proof that LSD belongs in routine rehabilitation.

The next test for the Fribourg finding is replication, not rapid rollout. Larger studies could establish whether the reported consolidation benefit appears consistently across different tasks, age groups, and levels of prior musical or motor experience. They could also clarify whether the effect depends on the timing of the dose, the practice session, or the follow up assessment.

Researchers will need to address the difficulty of masking psychedelic studies. Participants often recognise whether they received LSD, which can affect effort, expectations, and self reported outcomes. Objective motor measurements, independent assessors, and carefully designed control conditions will therefore remain central to the work.

The University of Fribourg study offers a focused starting point. It links a single dose to later performance on a defined piano sequence, reports a 32.8% advantage over placebo during consolidation, and keeps its conclusions narrow. That combination makes the result useful without making it definitive.

The findings also fit into Switzerland's longer history with LSD research. Basel chemist Albert Hofmann discovered the substance in 1938 and later became closely associated with its psychedelic effects. Decades later, the Fribourg study is examining a different question: how a psychedelic may influence the mechanics of learning. The answer will depend on evidence from larger and more rigorous trials.